Eli Lilly: three launches inside eighteen months, limited competition on two

The economics turn on exclusivity. A launch with limited competition earns close to monopoly economics for its exclusivity window, and the window length is known in advance. The pipeline evidence is regulatory rather than commercial. Three filings have accepted review dates inside eighteen months and two face no filed competitor. The position: long on Eli Lilly, entry locked at publication and the exit dated rather than open-ended. The target is stated in the call block above and the horizon with it. Sized to the catalyst rather than to conviction, with the invalidation written into the kill-switch card instead of left implicit. A new entrant re-entering the category would restart deflation, and the pricing argument would go with it.